Nicotinic receptors and Alzheimer's disease

Current Medical Research and Opinion

Volumn 19, Issue 3, 2003, Pages 169-177

  Bourin, Michel ^a   Ripoll, Nadège ^a   Dailly, Eric ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Alzheimer's disease; Cholinergic transmission; Cholinesterase inhibitors; Galantamine; Nicotinic receptors

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ABT 148; AMYLOID BETA PROTEIN; ANABASINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; EPIBATIDINE; GALANTAMINE; MECAMYLAMINE; METHYLLYCACONITINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; RIVASTIGMINE; SI B1553A;

ALZHEIMER DISEASE; ATTENTION; CELL MEMBRANE; CHOLINERGIC TRANSMISSION; COGNITION; HUMAN; NONHUMAN; PATHOGENESIS; POLYMERIZATION; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; ANIMALS; HUMANS; RECEPTORS, NICOTINIC;

EID: 0038244830     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001631     Document Type: Review

References (112)

1. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90
2. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 1992;58:529-41
3. Levin ED, Rose JE. Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Brain Res Bull 1991;27:125-8
4. James JR, Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav Genet 1995;25:149-59
5. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998;138:217-30
6. Newhouse PA, Kelton M. Clinical aspects of nicotinic agents: therapeutic applications in central nervous system disorders. In Clementi F, Gotti C, Fornasari D, eds. Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors. Heidelberg: Springer, 1999:779-812
7. Levin ED, Rose JE, McGurk SR, Butcher LL. Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav Neural Biol 1990;53:103-12
8. Levin ED, Briggs SJ, Christopher NC, Rose JE. Prenatal nicotine exposure and cognitive performance in rats. Neurotoxicol Teratol 1993;15:251-60
9. Levin ED, Rose JE, Abood L. Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav 1995;51:369-73
10. Levin ED, Toll K, Chang G, et al. Epibatidine, a potent nicotinic agonist: effects on learning and memory in the radial-arm maze. Med Chem Res 1996;6:543-54
11. Levin ED, Damaj MI, Glassco W, May EL, Martin BR. Bridged nicotine, isonicotine and norisonicotine effects on working memory performance of rats in the radial-arm maze. Drug Dev Res 1999;46:107-11
12. Felix R, Levin ED. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience 1997;81:1009-17
13. Hecht K, Poppei M, Hecht T, Postnow JW, Moritz V, Baumann R. Learning and memory processes during postnatal ontogenesis in rats with spontaneous hypertension. Acta Biol Med Ger 1978;37:1471-8
14. Gattu M, Terry AV, Jr, Pauly JR, Buccafusco JJ. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors. Part II. Brain Res 1997;771:104-14
15. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 1995;674:2529
16. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997;42:159-63
17. Nanri M, Kasahara N, Yamamoto J, Miyake H, Watanabe H. GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol 1997;74:285-9
18. Meyer EM, King MA, Meyers C. Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Res 1998;786:252-4
19. Lloyd GK, Menzaghi F, Bontempi B, Suto C, Siegel R, Akong M, Stauderman K, Velicelebi G, Johnson E, Harpold MM, Rao TS, Sacaan AI, Chavez-Noriega LE, Washburn MS, Vernier JM, Cosford ND, McDonald LA. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci 1998;62:1601-6
20. Flynn DD, Mash DC. Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 1986;47:1948-54
21. Warpman U, Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 1995;6:2419-23
22. Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, Steur EN, Maelicke A, Albuquerque EX, Schroder H. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 1999;11:2551-65
23. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000;74:237-43
24. Perry EK, Martin-Ruiz CM, Court JA. Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol 2001;24:63-8
25. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 2001;49:175-84
26. Hellstrom-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res 1999;66:94-103
27. Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO. Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology 1988;38:931-7
28. Gitelman DR, Prohovnik I. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging 1992;13:313-18
29. Newhouse PA, Potter A, Corwin J, Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology (Berl) 1992;108:480-4
30. Newhouse PA, Potter A, Lenox RH. Effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med Chem Res 1993;2:628-42
31. Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994;10:93-107
32. Spilich GJ, June L, Renner J. Cigarette smoking and cognitive performance. Br J Addict 1992;87:1313-26
33. Heishman SJ, Taylor RC, Henningfield JE. Nicotine and smoking: a review of effects on human performance. Exp Clin Psychopharmacol 1994;2:355-95
34. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 1999;142:334-42
35. Nordberg A. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. Acta Neurol Scand 1993;(Suppl) 149:62-5
36. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994;13:131-44
37. Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 1995;15:1231-44
38. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995;57:521-46
39. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 1991;350:235-8
40. Unwin N. Nicotinic acetylcholine receptor at 9 A resolution. J Mol Biol 1993;229:1101-24
41. Unwin N. Projection structure of the nicotinic acetylcholine receptor: distinct conformations of the alpha subunits. J Mol Biol 1996;257:586-96
42. Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994;79:705-15
43. Le Novere N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 1995;40:155-72
44. Gotti C, Carbonnelle E, Moretti M, Zwart R, Clementi F. Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? Behav Brain Res 2000;113:183-92
45. Papke RL. The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity. Prog Neurobiol 1993;41:509-31
46. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 1993;13:596-604
47. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995;269:1692-6
48. Role LW, Berg DK. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 1996;16:1077-85
49. Castro NG, Albuquerque EX. alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys J 1995;68:516-24
50. Mike A, Albuquerque EX. A kinetic analysis of acetylcholineand choline-activated α7-containing nicotinic receptor channels in hippocampal neurons [Abstr.]. Proc Mtg Neuronal Nicotinic Receptors, Venice, Italy. 1999:69
51. Alkondon M, Albuquerque EX. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. 1. Pharmacological and functional evidence for distinct structural subtypes. J Pharmacol Exp Ther 1993;265:1455-73
52. Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 1997;9:2734-42
53. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000;393:165-70
54. Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, Swanson LW. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol 1989;284:314-35
55. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 1997;53:199-237
56. Wada E, McKinnon D, Heinemann S, Patrick J, Swanson LW. The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family (alpha 5) in the rat central nervous system. Brain Res 1990;526:45-53
57. Charpantier E, Barneoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 1998;9:3097-101
58. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988;275:216-40
59. Mesulam MM, Geula C, Bothwell MA, Hersh LB. Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons. J Comp Neurol 1989;283:611-33
60. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997;390:401-4
61. Lang W, Henke H. Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer-type patients. Brain Res 1983;267:271-80
62. Court J, Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 1995;9(Suppl 2):6-14
63. Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, Perry E, Nordberg A. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 2001;22:115-26
64. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117-36
65. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci 1999;19:2693-705
66. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997;20:92-8
67. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999;22:555-61
68. Albuquerque EX, Pereira EF, Mike A, Eisenberg HM, Maelicke A, Alkondon M. Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance. Behav Brain Res 2000;113:131-41
69. Xu W, Orr-Urtreger A, Nigro F, Gelber S, Sutcliffe CB, Armstrong D, Patrick JW, Role LW, Beaudet AL, De Biasi M. Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. J Neurosci 1999;19:9298-305
70. Mihailescu S, Drucker-Colin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 2000;31:131-44
71. Court JA, Lloyd S, Johnson M, Griffiths M, Birdsall NJ, Piggott MA, Oakley AE, Ince PG, Perry EK, Perry RH. Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Dev Brain Res 1997;101:93-105
72. Pugh PC, Berg DK. Neuronal acetylcholine receptors that bind alpha-bungarotoxin mediate neurite retraction in a calciumdependent manner. J Neurosci 1994;14:889-96
73. Zoli M. NAChR in development and ageing. In Clementi F, Fornasari D, Gotti C, eds. Neuronal Nicotinic Receptors: Handbook of Experimental Pharmacology. Berlin: Springer-Verlag, 2000
74. Pauly JR, Grun EU, Collins AC. Glucocorticoid regulation of sensitivity to nicotine. In Lippiello PM, Collins AC, Gray JA, Robinson JH, eds. The Biology of Nicotine: Current Research Issues. New York: Raven Press, 1992:121-37
75. Radcliffe KA, Fisher JL, Gray R, Dani JA. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann N Y Acad Sci 1999;868:591-610.
76. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid. Neurochem Res 1992;17:265-71
77. Levin ED, Bettegowda C. Nicotinic-NMDA interactions with working and reference memory [Abstr.]. Soc Neurosci Abstr 1997;23:216
78. Radcliffe KA, Dani JA. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 1998;18:7075-83
79. Dani JA, Radcliffe KA, Pidoplichko VI. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur J Pharmacol 2000;393:31-8
80. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001;49:166-74
81. Fisher JL, Dani JA. Nicotinic receptors on hippocampal cultures can increase synaptic glutamate currents while decreasing the NMDA-receptor component. Neuropharmacology 2000;39:2756-69
82. Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S, Kimura J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res 1997;765:135-40
83. Shimohama S, Akaike A, Kimura J. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptormediated inhibition of nitric oxide formation. Ann N Y Acad Sci 1996;777:356-61
84. Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res 1996;719:36-44
85. Li Y, Papke RL, He YJ, Millard WJ, Meyer EM. Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells. Brain Res 1999;830:218-25
86. 2+ ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci 1997;17:576-85
87. Alkondon M, Pereira EF, Albuquerque EX. α-bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res 1998;810:257-63
88. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000;20:66-75
89. Adams CE, Freedman R. Nicotinic antagonist alpha-bungarotoxin binding to rat hippocampal neurons containing nitric oxide synthase. Brain Res 1997;776:111-16
90. Segovia G, Porras A, Mora F. Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat. Neuroreport 1994;5:1937-40
91. Isaacson JS, Solis JM, Nicoll RA. Local and diffuse synaptic actions of GABA in the hippocampus. Neuron 1993;10:165-75
92. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-70
93. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998;8:447-53
94. Zeng H, Zhang Y, Peng L, Shao H, Menon NK, Yang J, Salomon AR, Freidland RP, Zagorski MG. Nicotine and amyloid formation. Biol Psychiatry 2001;49:248-57
95. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-53
96. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000;275:5626-32
97. Dineley KT, Bell KA, Bui D, Sweatt JD. β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 2002;277:25056-61
98. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-33
99. Blum S, Moore AN, Adams F, Dash PK. A mitogen-activated protein kinase cascade in the CA1/CA2 subfield of the dorsal hippocampus is essential for long-term spatial memory. J Neurosci 1999;19:3535-44
100. Mills J, Laurent Charest D, Lam F, Beyreuther K, Ida N, Pelech SL, Reiner PB. Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 1997;17:9415-22
101. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002;110:199-211
102. Alkondon M, Braga MF, Pereira EF, Maelicke A, Albuquerque EX. α7 Nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol 2000;393:59-67
103. Parpura-Gill A, Beitz D, Uemura E. The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res 1997;754:65-71
104. Tamura Y, Sato Y, Akaike A, Shiomi H. Mechanisms of cholecystokinin-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 1992;592:317-25
105. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 1998;792:331-4
106. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. α7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a β-amyloid-induced neurotoxicity. J Biol Chem 2001;276:13541-6
107. Nordberg A, Winblad B. Reduced number of [3H]nicotine and [3H] acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 1986;72:115-19
108. Stahl SM. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action. J Clin Psychiatry 2000;61:813-14
109. Flicker L. Acetylcholinesterase inhibitors for Alzheimer's disease. BMJ 1999;318:615-16
110. Kem WR. The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169-81
111. National Institute for Clinical Excellence. Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. (Technology Appraisal Guidance - No. 19.) London, UK, January 2001
112. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66